Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Articles|August 15, 2022
Lt. Col. Matthew Banti, MD, discusses his unique experience as a urologist in the military
On this podcast, Lieutenant Colonel Matthew Banti, MD, FACS, a recent graduate of the Urologic Oncology fellowship at the University of Kansas Health System, is interviewed about his career journey as a urologist in the United States Army.
Advertisement
In this podcast interview, Lt. Col. Matthew Banti, MD, FACS, a recent graduate of the Urologic Oncology fellowship at the University of Kansas Health System, provides great insight on his unique journey. He discusses the life of a urologist in the Army and the characteristics that make an optimal physician within the military. Dr. Banti also offers his thoughts on his life overall as a urologic oncologist and how he can best serve the country as an extremely specialized professional.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5